Table 1.
Baseline characteristics.
| Level | The whole cohort (n=304) |
Training cohort (n=203) |
Validation cohort (n=101) |
P | |
|---|---|---|---|---|---|
| Gender | Male | 268 (88.2) | 180 (88.7) | 88 (87.1) | 0.839 |
| Female | 36 (11.8) | 23 (11.3) | 13 (12.9) | ||
| Age (years) | ≤50 | 100 (32.9) | 65 (32.0) | 35 (34.7) | 0.741 |
| >50 | 204 (67.1) | 138 (68.0) | 66 (65.3) | ||
| Etiology | HBV | 261 (85.9) | 174 (85.7) | 87 (86.1) | 1 |
| Other | 43 (14.1) | 29 (14.3) | 14 (13.9) | ||
| ECOG | 0 score | 246 (80.9) | 165 (81.3) | 81 (80.2) | 0.943 |
| 1 score | 58 (19.1) | 38 (18.7) | 20 (19.8) | ||
| Child-Pugh stage | A | 280 (92.1) | 187 (92.1) | 93 (92.1) | 1 |
| B | 24 (7.9) | 16 (7.9) | 8 (7.9) | ||
| Tumor size (cm) | ≤ 10cm | 216 (71.1) | 140 (69.0) | 76 (75.2) | 0.316 |
| > 10cm | 88 (28.9) | 63 (31.0) | 25 (24.8) | ||
| Tumor number | 1 lesion | 102 (33.6) | 64 (31.5) | 38 (37.6) | 0.449 |
| 2-3 lesions | 48 (15.8) | 35 (17.2) | 13 (12.9) | ||
| >3 lesions | 154 (50.7) | 104 (51.2) | 50 (49.5) | ||
| BCLC stage | B | 57 (18.8) | 34 (16.7) | 23 (22.8) | 0.266 |
| C | 247 (81.2) | 169 (83.3) | 78 (77.2) | ||
| MVI | No | 121 (39.8) | 74 (36.5) | 47 (46.5) | 0.117 |
| Yes | 183 (60.2) | 129 (63.5) | 54 (53.5) | ||
| Metastasis | No | 182 (59.9) | 123 (60.6) | 59 (58.4) | 0.810 |
| Yes | 122 (40.1) | 80 (39.4) | 42 (41.6) | ||
| AFP (ng/mL) | (median[IQR]) | 366.00 [11.25,8789.25] | 285.00 [10.95,7966.00] | 466.00 [14.60,9424.00] | 0.515 |
| PIVKA-II (mAU/mL) | (median[IQR]) | 3332.50 [209.75,18917.75] | 3873.00 [276.50,21632.00] | 2721.00 [192.00,16599.00] | 0.472 |
Data are reported as n (%).
AFP, alpha-fetoprotein; BCLC stage, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; MVI, macrovascular invasion; PIVKA-II, Protein Induced by Vitamin K Absence or Antagonist-II.